İsKender İnCe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
İsKender İnCe has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Erdem Göker
Center for Drug R&D and Pharmacokinetic Applications (ARGEFAR), Ege University, Izmir, Turkey; Department of Medical Oncology, Ege University Faculty of Medicine, Izmir, Turkey
4 shared publicationsYeliz Yıldırım
Center for Drug Research and Pharmacokinetic Applications (ARGEFAR), Ege University, Izmir, Turkey
4 shared publications- Ayça Mehmetoğlu Al
EGE ÜNİVERSİTESİ, FEN BİLİMLERİ ENSTİTÜSÜ, BİYOTEKNOLOJİ ANABİLİM DALI (DİSİPLİNLERARASI)
2 shared publications Barış Gümüştaş
Center for Drug Research and Pharmacokinetic Applications (ARGEFAR), Ege University, Izmir, Turkey
2 shared publicationsGünnur Güler
2 shared publications- Yeliz Yıldırım
Department of Chemistry, Faculty of Science, Ege University, İzmir 35040, Türkiye
2 shared publications
Latest Publications
- 30 September 2026
- Published by Celal Bayar University Journal of Science in Celal Bayar Üniversitesi Fen Bilimleri Dergisi
- Vol. 22 (3) , 746-769
Synthesis And Characterization Of Thymoquinone-Loaded Nanoparticle
Thymoquinone (TQ), a bioactive compound derived from Nigella sativa, exhibits strong anticancer activity; however, its clinical application is limited by poor aqueous solubility and low bioavailability. In this study, an alginate-coated poly(lactic-co-glycolic acid) (PLGA) nanoparticle system was developed to improve TQ stability and provide controlled release. Nanoparticles were prepared by nanoprecipitation and characterized in terms of encapsulation efficiency, particle size, polydispersity index (PDI), zeta potential, and morphology using FTIR, SEM, and TEM. TQ quantification and release studies were performed by HPLC. The optimized nanoparticles showed a mean particle size of 178.1 ± 1.41 nm, encapsulation efficiency of 75.9 ± 0.75%, PDI of 0.4, and zeta potential of −25.55 mV. After 72 h, cumulative TQ release reached 81.7% at pH 5.5 and 75.7% at pH 7.4, indicating pH-responsive release behavior. Overall, the alginate-coated PLGA nanoparticles demonstrated potential as a controlled TQ delivery system for cancer therapy.
- 30 September 2026
- Published by Celal Bayar University Journal of Science in Celal Bayar Üniversitesi Fen Bilimleri Dergisi
- Vol. 22 (3) , 746-769
Synthesis And Characterization Of Thymoquinone-Loaded Nanoparticle
Thymoquinone (TQ), a bioactive compound derived from Nigella sativa, exhibits strong anticancer activity; however, its clinical application is limited by poor aqueous solubility and low bioavailability. In this study, an alginate-coated poly(lactic-co-glycolic acid) (PLGA) nanoparticle system was developed to improve TQ stability and provide controlled release. Nanoparticles were prepared by nanoprecipitation and characterized in terms of encapsulation efficiency, particle size, polydispersity index (PDI), zeta potential, and morphology using FTIR, SEM, and TEM. TQ quantification and release studies were performed by HPLC. The optimized nanoparticles showed a mean particle size of 178.1 ± 1.41 nm, encapsulation efficiency of 75.9 ± 0.75%, PDI of 0.4, and zeta potential of −25.55 mV. After 72 h, cumulative TQ release reached 81.7% at pH 5.5 and 75.7% at pH 7.4, indicating pH-responsive release behavior. Overall, the alginate-coated PLGA nanoparticles demonstrated potential as a controlled TQ delivery system for cancer therapy.
- Open Access
- 26 June 2026
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 30 (7)
Preparation and In Vitro Characterization of Quercetin and Chlorhexidine-loaded PLGA Nanoparticles for Oral Biofilm-Associated Pathologies
Objectives: This study aimed to develop and evaluate a dual-drug-loaded PLGA nanoparticle system incorporating quercetin (QUE) and chlorhexidine (CHX) for localized, sustained delivery, with potential application in biofilm-associated pathologies. Materials and methods: Single- and dual-drug systems containing CHX and QUE at different concentrations (1.5%, 5%, and 15%) were successfully loaded into poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) with high encapsulation efficiency. Physicochemical characterization was performed using dynamic light scattering (DLS), zeta potential analysis, SEM-EDX, FTIR, and thermal analysis (DSC and TGA). Release kinetics of QUE- and CHX-loaded nanoparticles were evaluated in an artificial saliva environment, and the amounts of CHX and QUE released were quantified by high-performance liquid chromatography (HPLC). Antimicrobial activity was assessed against Staphylococcus aureus and Escherichia coli using the disc diffusion method. Results: The prepared nanoparticles displayed spherical morphology with sizes ranging from 54.08 to 356.1 nm and zeta potentials from − 2.11 to -12.46 mV, indicating colloidal stability. FTIR and thermal analysis confirmed molecular dispersion of drugs and polymer-drug interactions. QUE showed complete release within 168 h in the single-drug system, whereas co-loading with CHX extended QUE retention, with 20% remaining after 240 h. CHX release reached ∼80% in both formulations. CHX/QUE nanoparticles demonstrated superior antibacterial activity compared to QUE-only systems, effectively inhibiting both Gram-positive and Gram-negative bacteria. Conclusion: These compounds and formulations are designed for clinical applications due to their slow, controlled release of the dual-active PLGA NP system.
- 26 June 2026
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 30 (7)
Open AccessPreparation and In Vitro Characterization of Quercetin and Chlorhexidine-loaded PLGA Nanoparticles for Oral Biofilm-Associated Pathologies
Objectives: This study aimed to develop and evaluate a dual-drug-loaded PLGA nanoparticle system incorporating quercetin (QUE) and chlorhexidine (CHX) for localized, sustained delivery, with potential application in biofilm-associated pathologies. Materials and methods: Single- and dual-drug systems containing CHX and QUE at different concentrations (1.5%, 5%, and 15%) were successfully loaded into poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) with high encapsulation efficiency. Physicochemical characterization was performed using dynamic light scattering (DLS), zeta potential analysis, SEM-EDX, FTIR, and thermal analysis (DSC and TGA). Release kinetics of QUE- and CHX-loaded nanoparticles were evaluated in an artificial saliva environment, and the amounts of CHX and QUE released were quantified by high-performance liquid chromatography (HPLC). Antimicrobial activity was assessed against Staphylococcus aureus and Escherichia coli using the disc diffusion method. Results: The prepared nanoparticles displayed spherical morphology with sizes ranging from 54.08 to 356.1 nm and zeta potentials from − 2.11 to -12.46 mV, indicating colloidal stability. FTIR and thermal analysis confirmed molecular dispersion of drugs and polymer-drug interactions. QUE showed complete release within 168 h in the single-drug system, whereas co-loading with CHX extended QUE retention, with 20% remaining after 240 h. CHX release reached ∼80% in both formulations. CHX/QUE nanoparticles demonstrated superior antibacterial activity compared to QUE-only systems, effectively inhibiting both Gram-positive and Gram-negative bacteria. Conclusion: These compounds and formulations are designed for clinical applications due to their slow, controlled release of the dual-active PLGA NP system.
- 9 February 2026
- Published by Taylor & Francis in Preparative Biochemistry & Biotechnology
- Vol. 56 (9) , 1-16
Folic acid-conjugated biopolymeric nanoparticles for targeted delivery of ixabepilone in breast cancer
Ixabepilone (IXA) is an FDA-approved chemotherapeutic agent for metastatic breast cancer; however, its clinical use is limited by severe toxicity to healthy tissues. To improve its therapeutic index, tumor-targeted drug delivery systems are required. In this study, IXA was encapsulated for the first time into folic acid (FA)-functionalized biopolymeric nanoparticles (NPs) to promote preferential delivery to folate receptor (FR)-expressing breast cancer cells. Chitosan (CS) and alginate (ALG) were conjugated with FA to fabricate targeted NP systems, and IXA-loaded formulations were optimized in terms of encapsulation efficiency and particle size. The optimized IXA/FACS and IXA/FAALG NPs exhibited encapsulation efficiencies of 51.3 ± 4.6% and 47.6 ± 5.0%, with mean particle sizes of approximately 155 nm. In vitro release studies under physiological and tumor-mimicking pH conditions demonstrated pH-responsive behavior, with increased IXA release at acidic pH (5.5). Release kinetics analysis indicated diffusion-controlled and anomalous transport mechanisms according to the Higuchi and Korsmeyer-Peppas models. Cytotoxicity studies on MDA-MB-231 and MCF-7 breast cancer cell lines revealed enhanced cytotoxic effects of FA-conjugated IXA-loaded NPs in FR-positive MDA-MB-231 cells compared to MCF-7 cells, suggesting preferential FR-mediated cellular interaction. Overall, FA-functionalized CS and ALG NPs represent a promising in vitro platform for targeted IXA delivery in FR-expressing breast cancer therapy.
- 9 February 2026
- Published by Taylor & Francis in Preparative Biochemistry & Biotechnology
- Vol. 56 (9) , 1-16
Folic acid-conjugated biopolymeric nanoparticles for targeted delivery of ixabepilone in breast cancer
Ixabepilone (IXA) is an FDA-approved chemotherapeutic agent for metastatic breast cancer; however, its clinical use is limited by severe toxicity to healthy tissues. To improve its therapeutic index, tumor-targeted drug delivery systems are required. In this study, IXA was encapsulated for the first time into folic acid (FA)-functionalized biopolymeric nanoparticles (NPs) to promote preferential delivery to folate receptor (FR)-expressing breast cancer cells. Chitosan (CS) and alginate (ALG) were conjugated with FA to fabricate targeted NP systems, and IXA-loaded formulations were optimized in terms of encapsulation efficiency and particle size. The optimized IXA/FACS and IXA/FAALG NPs exhibited encapsulation efficiencies of 51.3 ± 4.6% and 47.6 ± 5.0%, with mean particle sizes of approximately 155 nm. In vitro release studies under physiological and tumor-mimicking pH conditions demonstrated pH-responsive behavior, with increased IXA release at acidic pH (5.5). Release kinetics analysis indicated diffusion-controlled and anomalous transport mechanisms according to the Higuchi and Korsmeyer-Peppas models. Cytotoxicity studies on MDA-MB-231 and MCF-7 breast cancer cell lines revealed enhanced cytotoxic effects of FA-conjugated IXA-loaded NPs in FR-positive MDA-MB-231 cells compared to MCF-7 cells, suggesting preferential FR-mediated cellular interaction. Overall, FA-functionalized CS and ALG NPs represent a promising in vitro platform for targeted IXA delivery in FR-expressing breast cancer therapy.
- 31 March 2021
- Published by Bentham Science Publishers Ltd. in Current Radiopharmaceuticals
- Vol. 14 (1) , 23-36
Thymoquinone Glucuronide Conjugated Magnetic Nanoparticle for Bimodal Imaging and Treatment of Cancer as a Novel Theranostic Platform
Background: Theranostic oncology combines therapy and diagnosis and is a new field of medicine that specifically targets the disease by using targeted molecules to destroy the cancerous cells without damaging the surrounding healthy tissues. Objective: We aimed to develop a tool that exploits enzymatic TQ release from glucuronide (G) for the imaging and treatment of lung cancer. We added magnetic nanoparticles (MNP) to enable magnetic hyperthermia and MRI, as well as 131I to enable SPECT imaging and radionuclide therapy. Methods: A glucuronide derivative of thymoquinone (TQG) was enzymatically synthesized and conjugated with the synthesized MNP and then radioiodinated with 131I. New Zealand white rabbits were used in SPECT and MRI studies, while tumor modeling studies were performed on 6–7- week-old nude mice utilized with bioluminescence imaging. Results: Fourier-transform infrared spectroscopy (FTIR) and nuclear magnetic resonance (NMR) spectra confirmed the expected structures of TQG. The dimensions of nanoparticles were below 10 nm and they had rather polyhedral shapes. Nanoparticles were radioiodinated with 131I with over 95% yield. In imaging studies, in xenograft models, tumor volume was significantly reduced in TQGMNP-treated mice but not in non-treated mice. Among mice treated intravenously with TQGMNP, xenograft tumor models disappeared after 10 and 15 days, respectively. Conclusion: Our findings suggest that TQGMNP in solid, semi-solid and liquid formulations can be developed using different radiolabeling nuclides for applications in multimodality imaging (SPECT and MRI). By altering the characteristics of radionuclides, TQGMNP may ultimately be used not only for diagnosis but also for the treatment of various cancers as an in vitro diagnostic kit for the diagnosis of beta glucuronidase-rich cancers.
- 31 March 2021
- Published by Bentham Science Publishers Ltd. in Current Radiopharmaceuticals
- Vol. 14 (1) , 23-36
Thymoquinone Glucuronide Conjugated Magnetic Nanoparticle for Bimodal Imaging and Treatment of Cancer as a Novel Theranostic Platform
Background: Theranostic oncology combines therapy and diagnosis and is a new field of medicine that specifically targets the disease by using targeted molecules to destroy the cancerous cells without damaging the surrounding healthy tissues. Objective: We aimed to develop a tool that exploits enzymatic TQ release from glucuronide (G) for the imaging and treatment of lung cancer. We added magnetic nanoparticles (MNP) to enable magnetic hyperthermia and MRI, as well as 131I to enable SPECT imaging and radionuclide therapy. Methods: A glucuronide derivative of thymoquinone (TQG) was enzymatically synthesized and conjugated with the synthesized MNP and then radioiodinated with 131I. New Zealand white rabbits were used in SPECT and MRI studies, while tumor modeling studies were performed on 6–7- week-old nude mice utilized with bioluminescence imaging. Results: Fourier-transform infrared spectroscopy (FTIR) and nuclear magnetic resonance (NMR) spectra confirmed the expected structures of TQG. The dimensions of nanoparticles were below 10 nm and they had rather polyhedral shapes. Nanoparticles were radioiodinated with 131I with over 95% yield. In imaging studies, in xenograft models, tumor volume was significantly reduced in TQGMNP-treated mice but not in non-treated mice. Among mice treated intravenously with TQGMNP, xenograft tumor models disappeared after 10 and 15 days, respectively. Conclusion: Our findings suggest that TQGMNP in solid, semi-solid and liquid formulations can be developed using different radiolabeling nuclides for applications in multimodality imaging (SPECT and MRI). By altering the characteristics of radionuclides, TQGMNP may ultimately be used not only for diagnosis but also for the treatment of various cancers as an in vitro diagnostic kit for the diagnosis of beta glucuronidase-rich cancers.
- 31 December 2020
- Published by Erzincan Universitesi Fen Bilimleri Ensitusu Dergisi in Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi
- Vol. 13 (3) , 956-961
Emulsion formulations of indomethacine and xylometazoline hydrochloride for intranasal delivery
Nasal administration has many advantages over nasal, parenteral or oral administration. Some drugs are ineffective when administered orally due to absorption and first pass metabolism. Therefore, if the aqueous solubility problem can be overcome, the intranasal route will be an alternative method for administration. In this study, emulsion formulation was proposed as a new approach in order to increase the duration of the indomethacin-xylometazoline hydrochloride combination in the nose. The pH value of F1 and F2 emulsions were determined 9.4 and as 5.6 respectively. The particle size of F1 and F2 formulations were found to be 136.8±24 nm and 269.5±66 nm respectively. Formulation of o/w emulsion IND and XYL may be considered as an alternative to iv and po administration. This administration of drugs may be delivery to achieve rapid onset of its pharmacological effect.
- 31 December 2020
- Published by Erzincan Universitesi Fen Bilimleri Ensitusu Dergisi in Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi
- Vol. 13 (3) , 956-961
Emulsion formulations of indomethacine and xylometazoline hydrochloride for intranasal delivery
Nasal administration has many advantages over nasal, parenteral or oral administration. Some drugs are ineffective when administered orally due to absorption and first pass metabolism. Therefore, if the aqueous solubility problem can be overcome, the intranasal route will be an alternative method for administration. In this study, emulsion formulation was proposed as a new approach in order to increase the duration of the indomethacin-xylometazoline hydrochloride combination in the nose. The pH value of F1 and F2 emulsions were determined 9.4 and as 5.6 respectively. The particle size of F1 and F2 formulations were found to be 136.8±24 nm and 269.5±66 nm respectively. Formulation of o/w emulsion IND and XYL may be considered as an alternative to iv and po administration. This administration of drugs may be delivery to achieve rapid onset of its pharmacological effect.
- 5 March 2020
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 324 (1) , 71-85
Synthesis and characterization of folic acid-chitosan nanoparticles loaded with thymoquinone to target ovarian cancer cells
- 5 March 2020
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 324 (1) , 71-85
Synthesis and characterization of folic acid-chitosan nanoparticles loaded with thymoquinone to target ovarian cancer cells
- 6 May 2014
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 20 (6) , 684-693
Development andin vitro/in vivoevaluation of immediate release perindopril tablets
Perindopril erbumine (PE) is a BCS (Biopharmaceutics Classification System) class 3 drug with high solubility and low permeability. It is an inhibitor of the enzyme that converts angiotensin I (Angiotensin Converting Enzyme, ACE) into angiotensin II as well as causing the degradation of the vasodilator bradykinin into an inactive heptapeptide. The aim of this study was to develop an alternative drug product by using a different salt of perindopril and to evaluate the bioequivalence between PE, not still licensed, and perindopril arginine (PA), licensed in many countries, and to prepare PE tablets by using direct compression method. Many different formulations were prepared, among which F3-coded formulation was only selected due to releasing of 98.03% active substance at 45th minute. Bioequivalence study was planned as a cross-designed, randomized, open-labeled, single-dose, single-center study and conducted in 24 male healthy volunteers via peroral route. The results of bioequivalence study were evaluated for Perindopril and Perindoprilat according to Cmax, tmax and AUC criteria. The geometric mean ratios (90% CI) of perindopril and perindoprilat followed test and reference drug were calculated for AUC0–t and Cmax, 105.946% (100.218–112.002%) and 110.437% (102.534–118.948%); 109.542% (98.364–121.992%) and 115.729% (101.031–132.565%), respectively. The 90% confidence intervals of them were found within the standard bioequivalence range (80–125%).
- 6 May 2014
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 20 (6) , 684-693
Development andin vitro/in vivoevaluation of immediate release perindopril tablets
Perindopril erbumine (PE) is a BCS (Biopharmaceutics Classification System) class 3 drug with high solubility and low permeability. It is an inhibitor of the enzyme that converts angiotensin I (Angiotensin Converting Enzyme, ACE) into angiotensin II as well as causing the degradation of the vasodilator bradykinin into an inactive heptapeptide. The aim of this study was to develop an alternative drug product by using a different salt of perindopril and to evaluate the bioequivalence between PE, not still licensed, and perindopril arginine (PA), licensed in many countries, and to prepare PE tablets by using direct compression method. Many different formulations were prepared, among which F3-coded formulation was only selected due to releasing of 98.03% active substance at 45th minute. Bioequivalence study was planned as a cross-designed, randomized, open-labeled, single-dose, single-center study and conducted in 24 male healthy volunteers via peroral route. The results of bioequivalence study were evaluated for Perindopril and Perindoprilat according to Cmax, tmax and AUC criteria. The geometric mean ratios (90% CI) of perindopril and perindoprilat followed test and reference drug were calculated for AUC0–t and Cmax, 105.946% (100.218–112.002%) and 110.437% (102.534–118.948%); 109.542% (98.364–121.992%) and 115.729% (101.031–132.565%), respectively. The 90% confidence intervals of them were found within the standard bioequivalence range (80–125%).